Mitchell C. C. Liu, MDCM FRCPC
Clinical Associate Professor
University of British Columbia (UBC)
Active Staff – Radiation Oncologist
British Columbia Cancer Agency (BCCA) – Vancouver Centre *
Director of Lung Cancer Radiation Oncology (BCCA) – Vancouver Centre *
Hospital Authority: Provincial Health Services
600 West 10th Avenue
Vancouver, BC V5Z 4E6
Phone: 604.877.6000 Fax: 604.877.0505
Major Clinical Focus – Lung, Gastrointestinal Tumors, Stereotactic Body Radiation Therapy ( Lung, Liver, Spine, Oligometastases)
• Doctor of Medicine and Master Of Surgery, University of McGill, Canada, 1991
• Radiation Oncology residency, McGill University, Canada, 1991-1995
• Radiation Oncology, Fellow of The Royal College of Physicians of Canada, Royal College of Physicians & Surgeons of Canada, Canada, 1995
• Certification in Radiation Oncology Corporation Professionnalle des Medecins du Quebec, Canada, 1995
• Certification in Radiation Oncology American board of Radiology, United States, 1996
• Fellowship, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States, 1995-1996
• Prostate Brachytherapy training, Seattle, Washington, United States, 1999
Biographic Summary ( Background, Academic Interests and Activities, Clinical Activities )
Mitchell C.C. Liu, MDCM, FRCPC is a Clinical Associate Professor of Radiation Oncology in the Department of Surgery, University of British Columbia. Dr. Liu completed his radiation oncology residency at McGill University and a radiation oncology fellowship at Massachusetts General Hospital in Boston.
He joined BCCA in 1998 and currently in the Lung and GI team. Dr. Liu’s particular areas of interest include: Application of technological innovations in Radiation Oncology, e.g, VMAT, IGRT, SBRT (lung, liver, spine); and investigating risk factors and predictive models for radiation therapy complications.
1. Palma DA, Haasbeek CJA, Rodrigues GB, Dahele M, Lock M, Bauman G, Olson R, Liu M, Panarotto J, Griffioen GH, Gaede S, Slotman B, Senan S. Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): Study Protocol for a Randomized Phase II Trial. BMC Cancer 2012;12:305.
2. Herbert C, Liu M, Tyldesley S, Morris WJ, Joffres M, Khaira M, Kwan W, Moiseenko, Pickles T. Biochemical Control with Radiotherapy Improves Overall Survival in Intermediate and High-Risk Prostate Cancer Patients Who Have an Estimated 10-Year Overall Survival of >90%. International Journal of Radiation Oncology Biology Physics 2012; 83(1):22-7.
3. Moiseenko V, Lapointe V, James K, Yin LS, Liu M, Pawlicki T. Biological Consequences of MLC Calibration Errors in IMRT Delivery and QA. Med Phys 2012;39(4):1917-24.
4. Keyes M, Spadinger I, Liu M, Pickles T, Pai H, Hayden A, Moravan V, Halperin R, McKenzie M, Kwan W, Agranovic A, Lapointe V, Morris WJ. Rectal toxicity and rectal dosimetry in low-dose-rate iodine-125 permanent prostate implants: A long-term study in 1006 patients. Brachytherapy 2012;11(3):199-208.
5. Cao F, Ramaseshan R, Corns R, Harrop S, Nuraney N, Steiner P, Aldridge S, Liu M, Carolan H, Agranovich A, Karvat A. A Three-Isocentre JaggedJunction_IMRT Approach for Craniospinal Irradiation without Beam Edge Matching for Field Junctions. Int J Rad Onc Bio Phys 2012;84(3):648-654.
6. Lund CR, Ma R, Liu M, Schellenberg D. The current patterns of practice for stereotactic body radiotherapy in Canada. International Journal of Radiation Oncology Biology Physics, 2011; 81(2) Supp, S559.
7. Lund CR, Liu M, Wu J, Carolan H, Olson R, Schellenberg D. The incidence of hippocampal metastases in non-small cell lung cancer (NSCLC): A consecutive population-based series of patients presenting to the British Columbia (BC) Cancer Agency. J Thorac Oncol, 2011;6(6) Suppl 2 (abstract MO08.07).
8. Lee R, Liu M, Moiseenko V. A new metric to predict rectal bleeding based on dose-surface properties. Medical Physics, 2011; 38, 3493.
9. Carson R, Morris WJ, Moiseenko V, Tyldesley S, Kosztyla R, Hamm J, Hui J, Jackson J, Sahota H, Liu M. The toxicity of dose escalated external beam radiation therapy after elective pelvic nodal irradiation – evaluating the utility of the QUANTEC rectal dose thresholds. European Journal of Cancer, 2011; 47, Supp 1, S493-S494.
10. Yin L, Shcherbinin S, Celler A, Thompson A, Fua TF, Liu M, Duzenli C, Gill B, Sheehan F, Powe J, Worsley D, Marks L, Moiseenko V. Incorporating quantitative single photon emission computed tomography into radiation therapy treatment planning for lung cancer: impact of attenuation and scatter correction on the single photon emission computed tomography-weighted mean dose and functional lung segmentation. Int J Radiat Oncol Biol Phys 2010; 78(2):587-94.
11. Liu M, Moiseenko V, Agranovich A, Karvat A, Kwan W, Salenh ZH, Apte AA, Deasy JO. Normal Tissue Complication Probability (NTCP) modeling of late rectal bleeding following external beam radiotherapy for prostate cancer; A Test of the QUANTEC recommended NTCP model. Acta Oncol 2010;49(7):1040-1044.
* The British Columbia Cancer Agency (BCCA)-Vancouver Centre (VC) is the largest academic cancer centre for the BCCA, located in downtown Vancouver and treating about one third of the radiation oncology cancer patients in the Province of BC. Over 4360 cancer patients are seen each year in the radiation oncology department. There are 20 Radiation Oncology (RO) physician faculty with full disease site specialization and clinical programs of excellence, 2 General Practice (Internist) Oncology Physicians, 3 Clinical Fellows and 10 RO residents. The BCCA-Vancouver Centre also has 17 physicists and a graduate training program in physics, 15 nurses, >60 radiation therapists clerks, secretaries and many others within radiation oncology. General capabilities include 9 Linacs (including Truebeam), 1 cobalt, VMAT (first developed in the BCCA-VC), IMRT, SBRT, IGRT, HDR and LDR brachytherapy suites, and Protons (at the TRIUMF centre). The Vancouver Centre radiation oncology department conducts all levels of research (basic, translational, clinical, population), and is the main educational institution in BC for the training of graduate (residents) and undergraduate (medical) students. The interdisciplinary Radiation Oncology team is part of the even larger multidisciplinary and provincial teams.